

**Supplementary Table S1. Duration of chemotherapy for patients**

<b>Control group</b>	<b>CTX regimen</b>	<b>CTX duration (weeks)</b>	<b>Reasons of withdrawing CTX</b>	<b>CIK group</b>	<b>CTX regimen</b>	<b>CTX duration (weeks)</b>	<b>Reasons of withdrawing CTX</b>
<b>1</b>	CAPOX	6	Refusal	<b>1</b>	CAPOX	18	Completion
<b>2</b>	CAPOX	18	Completion	<b>2</b>	FOLFOX	4	Refusal
<b>3</b>	FOLFOX	20	Completion	<b>3</b>	CAPOX	15	Hand-foot syndrome
<b>4</b>	CAPOX	30	Completion	<b>4</b>	CAPOX	24	Completion
<b>5</b>	FOLFOX	24	Completion	<b>5</b>	CAPOX	21	Completion
<b>6</b>	FOLFOX	24	Completion	<b>6</b>	FOLFOX	20	Refusal
<b>7</b>	FOLFOX	24	Completion	<b>7</b>	CAPOX	18	Refusal
<b>8</b>	CAPOX	18	Completion	<b>8</b>	CAPOX	24	Completion
<b>9</b>	CAPOX	24	Completion	<b>9</b>	CAPOX	24	Completion
<b>10</b>	FOLFOX	24	Completion	<b>10</b>	CAPOX	24	Completion
<b>11</b>	FOLFOX	24	Completion	<b>11</b>	FOLFOX	10	Arrhythmia
<b>12</b>	FOLFOX	24	Completion	<b>12</b>	CAPOX	24	Completion
<b>13</b>	FOLFOX	20	Refusal	<b>13</b>	CAPOX	24	Completion
<b>14</b>	CAPOX	24	Completion	<b>14</b>	CAPOX	24	Completion
<b>15</b>	CAPOX	24	Completion	<b>15</b>	CAPOX	24	Completion
<b>16</b>	CAPOX	18	Completion	<b>16</b>	Capecitabine	12	Myelosuppression
<b>17</b>	Capecitabine	24	Completion	<b>17</b>	CAPOX	24	Completion
<b>18</b>	CAPOX	24	Completion	<b>18</b>	FOLFOX	10	Gastrointestinal reaction
<b>19</b>	CAPOX	18	Refusal	<b>19</b>	CAPOX	24	Completion
<b>20</b>	FOLFOX	24	Completion	<b>20</b>	CAPOX	24	Completion
<b>21</b>	Capecitabine	21	Completion	<b>21</b>	FOLFOX	12	Refusal
<b>22</b>	CAPOX	18	Completion	<b>22</b>	CAPOX	24	Completion
<b>23</b>	FOLFOX	12	Refusal	<b>23</b>	CAPOX	18	Completion

---

<b>24</b>	FOLFOX	10	Refusal	<b>24</b>	CAPOX	24	Completion
<b>25</b>	CAPOX	21	Completion	<b>25</b>	FOLFOX	24	Completion
<b>26</b>	FOLFOX	12	Unknown	<b>26</b>	CAPOX	24	Completion
<b>27</b>	Capecitabine	18	Completion	<b>27</b>	CAPOX	24	Completion
<b>28</b>	FOLFOX	24	Completion	<b>28</b>	CAPOX	24	Completion
<b>29</b>	CAPOX	18	Completion	<b>29</b>	CAPOX	24	Completion
<b>30</b>	CAPOX	24	Completion	<b>30</b>	CAPOX	24	Completion
<b>31</b>	FOLFOX	24	Completion	<b>31</b>	FOLFOX	20	Completion
<b>32</b>	CAPOX	24	Completion	<b>32</b>	CAPOX	6	Diarrhea
<b>33</b>	CAPOX	6	Unknown	<b>33</b>	CAPOX	24	completion
<b>34</b>	CAPOX	24	Completion	<b>34</b>	FOLFOX	8	Gastrointestinal reaction
<b>35</b>	CAPOX	24	Completion	<b>35</b>	CAPOX	24	Completion
<b>36</b>	CAPOX	24	Completion	<b>36</b>	CAPOX	18	Gastrointestinal reaction
<b>37</b>	FOLFOX	20	Refusal	<b>37</b>	CAPOX	24	Completion
<b>38</b>	CAPOX	18	Completion	<b>38</b>	CAPOX	24	Completion
<b>39</b>	CAPOX	18	Completion	<b>39</b>	CAPOX	18	Unknown
<b>40</b>	CAPOX	24	Completion	<b>40</b>	CAPOX	18	Gastrointestinal reaction
<b>41</b>	CAPOX	18	Refusal	<b>41</b>	CAPOX	24	Completion
<b>42</b>	CAPOX	24	Completion	<b>42</b>	CAPOX	24	Completion
<b>43</b>	FOLFOX	22	Completion	<b>43</b>	CAPOX	18	Unknown
<b>44</b>	CAPOX	21	Completion	<b>44</b>	CAPOX	33	Completion
<b>45</b>	CAPOX	21	Completion	<b>45</b>	Capecitabine	24	Completion
<b>46</b>	CAPOX	24	Completion	<b>46</b>	CAPOX	24	Completion
<b>47</b>	FOLFOX	12	Refusal	<b>47</b>	CAPOX	24	Completion
<b>48</b>	FOLFOX	16	Unknown	<b>48</b>	FOLFOX	24	Completion
<b>49</b>	CAPOX	24	Completion	<b>49</b>	FOLFOX	24	Completion

---

<b>50</b>	CAPOX	18	Completion	<b>50</b>	CAPOX	18	Myelosuppression
<b>51</b>	CAPOX	33	Completion	<b>51</b>	CAPOX	24	Completion
<b>52</b>	CAPOX	18	Completion	<b>52</b>	CAPOX	24	Completion
<b>53</b>	CAPOX	18	Gastrointestinal reaction	<b>53</b>	CAPOX	24	Completion
<b>54</b>	CAPOX	18	Completion	<b>54</b>	FOLFOX	20	Refusal
<b>55</b>	CAPOX	18	Refusal	<b>55</b>	FOLFOX	24	Completion
<b>56</b>	FOLFOX	24	Completion	<b>56</b>	Capecitabine	12	Gastrointestinal reaction
<b>57</b>	CAPOX	18	Completion	<b>57</b>	Capecitabine	3	Refusal
<b>58</b>	CAPOX	24	Completion	<b>58</b>	Capecitabine	21	Arrhythmia
<b>59</b>	CAPOX	18	Refusal	<b>59</b>	CAPOX	24	Completion
<b>60</b>	CAPOX	24	Completion	<b>60</b>	Capecitabine	24	Completion
<b>61</b>	Capecitabine	18	Myelosuppression				
<b>62</b>	CAPOX	24	Completion				

CIK, cytokine-induced killer cell. CTX, chemotherapy. CAPOX, Capecitabine + Oxaliplatin. FOLFOX, Oxaliplatin + 5-fluorouracil.

**Supplementary Table S2. The detailed information of CIK cell treatment**

CIK group	Cycles of CIK cell treatment	Mean number	Mean number	DFS (months)	Recurrence	OS (months)	Survival
		of total infused CIK cells ( $\times 10^{10}$ )	of total infused CIK cells per Kg BW ( $\times 10^8$ )				
1	5	1.210	1.494	124	Yes	127	Alive
2	6	1.230	1.662	130	No	130	Alive
3	20	1.239	1.877	98	No	98	Alive
4	23	1.216	1.762	118	No	118	Alive
5	7	1.215	1.687	21	Yes	37	Death
6	5	1.230	2.278	11	No	11	Alive
7	24	1.225	2.150	86	No	86	Alive
8	63	1.208	2.415	97	No	97	Alive
9	16	1.240	2.479	39	Yes	56	Death
10	33	1.230	2.365	88	No	88	Alive
11	9	1.270	2.822	11	Yes	11	Death
12	20	1.224	1.883	63	No	63	Alive
13	30	1.231	1.539	71	No	71	Alive
14	5	1.182	2.412	17	Yes	29	Death
15	5	1.246	2.596	59	No	59	Alive
16	10	1.232	2.464	71	No	71	Alive
17	11	1.233	2.465	70	No	70	Alive
18	18	1.228	1.497	69	No	69	Alive
19	54	1.230	2.236	67	No	67	Alive
20	35	1.244	1.382	61	No	61	Alive
21	8	1.225	2.450	12	No	12	Alive
22	9	1.224	2.041	68	No	68	Alive
23	15	1.227	1.168	48	No	48	Alive
24	46	1.224	1.569	25	Yes	64	Death

<b>25</b>	17	1.235	2.469	83	No	83	Alive
<b>26</b>	17	1.236	2.208	65	No	65	Alive
<b>27</b>	8	1.219	2.031	20	Yes	52	Alive
<b>28</b>	8	1.225	2.042	36	No	36	Alive
<b>29</b>	8	1.233	1.896	60	No	60	Alive
<b>30</b>	24	1.220	1.769	49	No	49	Alive
<b>31</b>	21	1.209	2.324	20	Yes	62	Alive
<b>32</b>	29	1.222	2.221	35	No	35	Alive
<b>33</b>	8	1.226	1.752	56	No	56	Alive
<b>34</b>	10	1.200	1.846	67	No	67	Alive
<b>35</b>	8	1.220	1.877	48	No	48	Alive
<b>36</b>	11	1.225	2.111	72	No	72	Alive
<b>37</b>	8	1.229	1.890	19	Yes	49	Alive
<b>38</b>	5	1.224	1.654	35	Yes	53	Alive
<b>39</b>	13	1.218	1.625	18	Yes	52	Alive
<b>40</b>	6	1.213	2.092	7	No	7	Alive
<b>41</b>	10	1.221	2.261	37	No	37	Alive
<b>42</b>	43	1.201	1.877	39	Yes	57	Alive
<b>43</b>	29	1.200	1.667	53	Yes	53	Alive
<b>44</b>	10	1.210	2.749	15	Yes	41	Alive
<b>45</b>	14	1.224	2.039	41	No	41	Alive
<b>46</b>	8	1.220	1.848	45	No	45	Alive
<b>47</b>	8	1.215	2.095	46	No	46	Alive
<b>48</b>	43	1.198	2.066	31	Yes	48	Alive
<b>49</b>	27	1.257	2.733	56	No	56	Alive
<b>50</b>	6	1.223	2.224	46	No	46	Alive
<b>51</b>	8	1.225	1.914	11	No	11	Alive
<b>52</b>	4	1.220	2.218	44	No	44	Alive
<b>53</b>	8	1.226	1.703	39	No	39	Alive

<b>54</b>	40	1.213	1.867	46	Yes	48	Death
<b>55</b>	10	1.218	2.100	52	No	52	Alive
<b>56</b>	10	1.230	1.864	35	No	35	Alive
<b>57</b>	19	1.198	2.349	28	No	28	Alive
<b>58</b>	17	1.188	2.285	91	No	91	Alive
<b>59</b>	22	1.252	1.605	32	No	32	Alive
<b>60</b>	12	1.261	2.292	28	No	28	Alive

---

CIK, cytokine-induced killer cell. BW, body weight. DFS, disease-free survival. OS, overall survival.

**Supplementary Table S3. The detailed survival information**

<b>Control group</b>	<b>Duration of chemotherapy (Weeks)</b>	<b>T stage</b>	<b>DFS (months)</b>	<b>Recurrence</b>	<b>OS (months)</b>	<b>Survival</b>	<b>CIK group</b>	<b>Duration of chemotherapy (Weeks)</b>	<b>T stage</b>	<b>DFS (months)</b>	<b>Recurrence</b>	<b>OS (months)</b>	<b>Survival</b>
<b>1</b>	6	4	20	Yes	51	Death	<b>1</b>	18	3	124	Yes	127	Alive
<b>2</b>	18	4	28	Yes	37	Alive	<b>2</b>	4	3	130	No	130	Alive
<b>3</b>	20	3	32	Yes	32	Alive	<b>3</b>	15	4	98	No	98	Alive
<b>4</b>	30	4	107	No	107	Alive	<b>4</b>	24	4	118	No	118	Alive
<b>5</b>	24	4	34	No	34	Alive	<b>5</b>	21	2	21	Yes	37	Death
<b>6</b>	24	3	86	No	86	Alive	<b>6</b>	20	3	11	No	11	Alive
<b>7</b>	24	1	45	No	45	Alive	<b>7</b>	18	4	86	No	86	Alive
<b>8</b>	18	4	31	Yes	105	Alive	<b>8</b>	24	4	97	No	97	Alive
<b>9</b>	24	4	25	Yes	37	Death	<b>9</b>	24	3	39	Yes	56	Death
<b>10</b>	24	3	3	Yes	13	Alive	<b>10</b>	24	4	88	No	88	Alive
<b>11</b>	24	3	13	Yes	30	Death	<b>11</b>	10	4	11	Yes	11	Death
<b>12</b>	24	2	102	No	102	Alive	<b>12</b>	24	4	63	No	63	Alive
<b>13</b>	20	3	88	No	88	Alive	<b>13</b>	24	3	71	No	71	Alive

<b>14</b>	24	3	103	No	103	Alive	<b>14</b>	24	3	17	Yes	29	Death
<b>15</b>	24	2	114	No	114	Alive	<b>15</b>	24	3	59	No	59	Alive
<b>16</b>	18	4	15	Yes	66	Death	<b>16</b>	12	4	71	No	71	Alive
<b>17</b>	24	3	99	No	99	Alive	<b>17</b>	24	4	70	No	70	Alive
<b>18</b>	24	3	93	No	93	Alive	<b>18</b>	10	3	69	No	69	Alive
<b>19</b>	18	3	72	No	72	Alive	<b>19</b>	24	3	67	No	67	Alive
<b>20</b>	24	4	18	Yes	22	Alive	<b>20</b>	24	2	61	No	61	Alive
<b>21</b>	21	4	11	Yes	27	Death	<b>21</b>	12	4	12	No	12	Alive
<b>22</b>	18	3	13	Yes	57	Alive	<b>22</b>	24	3	68	No	68	Alive
<b>23</b>	12	4	13	Yes	39	Death	<b>23</b>	18	3	48	No	48	Alive
<b>24</b>	10	3	40	Yes	87	Death	<b>24</b>	24	3	25	Yes	64	Death
<b>25</b>	21	4	6	Yes	9	Death	<b>25</b>	24	3	83	No	83	Alive
<b>26</b>	12	4	24	Yes	62	Death	<b>26</b>	24	4	65	No	65	Alive
<b>27</b>	18	3	81	No	81	Alive	<b>27</b>	24	3	20	Yes	52	Alive
<b>28</b>	24	4	30	No	30	Alive	<b>28</b>	24	3	36	No	36	Alive
<b>29</b>	18	3	54	No	54	Alive	<b>29</b>	24	4	60	No	60	Alive
<b>30</b>	24	4	12	Yes	64	Alive	<b>30</b>	24	3	49	No	49	Alive




<b>31</b>	24	4	38	Yes	40	Alive	<b>31</b>	20	3	20	Yes	62	Alive
<b>32</b>	24	4	51	No	51	Alive	<b>32</b>	6	2	35	No	35	Alive
<b>33</b>	6	3	36	No	36	Alive	<b>33</b>	24	2	56	No	56	Alive
<b>34</b>	24	3	80	No	80	Alive	<b>34</b>	8	4	67	No	67	Alive
<b>35</b>	24	4	54	No	54	Alive	<b>35</b>	24	4	48	No	48	Alive
<b>36</b>	24	3	77	No	77	Alive	<b>36</b>	18	3	72	No	72	Alive
<b>37</b>	20	3	22	Yes	69	Alive	<b>37</b>	24	4	19	Yes	49	Alive
<b>38</b>	18	4	58	No	58	Alive	<b>38</b>	24	3	35	Yes	53	Alive
<b>39</b>	18	3	25	No	25	Alive	<b>39</b>	18	4	18	Yes	52	Alive
<b>40</b>	24	4	15	Yes	22	Alive	<b>40</b>	18	3	7	No	7	Alive
<b>41</b>	18	3	10	Yes	20	Death	<b>41</b>	24	4	37	No	37	Alive
<b>42</b>	24	3	54	No	54	Alive	<b>42</b>	24	3	39	Yes	57	Alive
<b>43</b>	22	4	48	No	48	Alive	<b>43</b>	18	4	53	Yes	53	Alive
<b>44</b>	21	4	13	Yes	25	Alive	<b>44</b>	33	4	15	Yes	41	Alive
<b>45</b>	21	4	12	Yes	17	Death	<b>45</b>	24	3	41	No	41	Alive
<b>46</b>	24	3	14	Yes	36	Death	<b>46</b>	24	4	45	No	45	Alive
<b>47</b>	12	3	24	Yes	30	Death	<b>47</b>	24	3	46	No	46	Alive


<b>48</b>	16	3	9	Yes	27	Death	<b>48</b>	24	3	31	Yes	48	Alive
<b>49</b>	24	3	51	No	51	Alive	<b>49</b>	24	4	56	No	56	Alive
<b>50</b>	18	4	17	Yes	46	Death	<b>50</b>	18	3	46	No	46	Alive
<b>51</b>	33	4	32	Yes	56	Alive	<b>51</b>	24	3	11	No	11	Alive
<b>52</b>	18	4	13	Yes	62	Death	<b>52</b>	24	3	44	No	44	Alive
<b>53</b>	18	3	8	Yes	21	Death	<b>53</b>	24	3	39	No	39	Alive
<b>54</b>	18	4	10	Yes	48	Death	<b>54</b>	20	4	46	Yes	48	Death
<b>55</b>	18	3	19	Yes	30	Alive	<b>55</b>	24	3	52	No	52	Alive
<b>56</b>	24	3	46	No	46	Alive	<b>56</b>	12	3	35	No	35	Alive
<b>57</b>	18	3	51	No	51	Alive	<b>57</b>	3	3	28	No	28	Alive
<b>58</b>	24	4	37	No	37	Alive	<b>58</b>	21	2	91	No	91	Alive
<b>59</b>	18	3	41	No	41	Alive	<b>59</b>	24	3	32	No	32	Alive
<b>60</b>	24	3	35	No	35	Alive	<b>60</b>	24	3	28	No	28	Alive
<b>61</b>	18	3	14	No	14	Alive							
<b>62</b>	24	3	38	No	38	Alive							

---


DFS, disease-free survival. OS, overall survival.



**Supplementary Figure S1. The phenotype of CIK cells before and after *in vitro* expansion.** The positive proportions of CD3<sup>+</sup>CD4<sup>+</sup>, CD3<sup>+</sup>CD8<sup>+</sup>, CD3<sup>-</sup>CD56<sup>+</sup>, and CD3<sup>+</sup>CD56<sup>+</sup> are shown (Upper). The results were from 5 patients and are represented as mean ± SEM (Lower). CIK, cytokine-induced killer cell. \**p* < 0.05.



**Supplementary Figure S2. Relationship between infused cell dose and patients' prognosis.** Based on the median of mean number of total infused CIK cells, patients were divided into high-dose CIK group and low-dose CIK group. CIK, cytokine-induced killer cell.



**Supplementary Figure S3. CIK cell treatment protocol.** CIK, cytokine-induced killer cells; CRC, colorectal cancer; W, week.